Flagship Ventures

Type: Company
Name: Flagship Ventures
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Atlas biotech gets $29M to create healing bacteria for the gut

Eight months after Flagship Ventures launched its biotech to develop drugs based on microorganisms in the human body, Atlas Venture today announced $29 million in financing for its entry into that field.Synlogic was founded last fall by Ankit Mahadevia, ... [Published Business First of Buffalo - Jul 22 2014]
First reported Jul 17 2014 - Updated Jul 18 2014 - 1 reports

How A Little Serendipity Led Acceleron to a Crippling Blood Disease

7/17/14 Follow @benthefidlerHow maddening is drug development? Sometimes, all the scientific literature in the world leads you one way, and your own data take you another. That’s why even experienced drug hunters often need a little luck to succeed. Just ... [Published Xconomy - Jul 17 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

Seventh Sense Biosystems Receives Notices of Allowance for Three U.S. Patents for TAP Blood Collection System

10:01 AM Eastern Daylight TimeCAMBRIDGE, Mass.--( BUSINESS WIRE )--Seventh Sense Biosystems, Inc., (7SBio), a leading developer of bloodcollection and diagnostic platforms, announced today the receipt ofnotices of allowance from the United States Patent ... [Published Business Wire - Jul 17 2014]
First reported Jul 16 2014 - Updated Jul 17 2014 - 1 reports

Seres Makes Push for First Drug, and IPO, of Microbiome Era

The first regulated therapy to emerge from the recent explosion of microbiome research is one step closer. And the company developing it, Seres Health, is stepping toward the first microbiome startup IPO, Xconomy has learned.The Cambridge, MA startup ... [Published Xconomy - Jul 16 2014]
Entities: IPOs, Bacteria, Push
First reported Jul 14 2014 - Updated Jul 15 2014 - 4 reports

Flagship brings aboard ex-Merck & Co exec Pomerantz as senior partner

Healthcare-focused early stage investment firm Flagship Ventures has hired former Merck & Co senior vice president Roger Pomerantz as a senior partner.Flagship said Pomerantz would provide strategic counsel and support to Flagship’s team and portfolio ... [Published AltAssets.net - Jul 15 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 1 reports

BetaBoston Four Boston biotech firms worth watching

It’s already a banner year for biotech in Massachusetts, with 11 firms going public  so far — a new record for a single year.In the past few months I’ve been taking a look at some of the companies in the next wave of promising biotechnology in Boston. Here ... [Published Boston Globe - Jul 07 2014]
First reported Jul 02 2014 - Updated Jul 02 2014 - 2 reports

Diagnostics developer T2 Biosystems files for a...

T2 Biosystems, which is developing diagnostics tests that screen for sepsis and hemostasis, filed on Wednesday with the SEC to raise up to $69 million in an initial public offering. The company claims that its technology platform will lead to an earlier ... [Published Nasdaq - Jul 02 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Moderna Appoints Genentech Alum to Lead New Venture Onkaido

Moderna Therapeutics Inc., whichraised $110 millionlast year, has hired a president to lead the first of multiple companies it plans to launch as it tries to extract maximum value from technology designed to enable a new class of messenger-RNA drugs.Biotechnology ... [Published Dow Jones Financial Information Services - Jul 01 2014]
First reported Jun 24 2014 - Updated Jun 25 2014 - 3 reports

VC-backed Editas Medicine hires CEO

Editas Medicine has hired Katrine S. Bosley as CEO. Previously, Bosley worked at Avila Therapeutics where she served as CEO. Based in Cambridge, Mass., Editas Medicine is a transformative genome editing firm. It is backed by Flagship Ventures, Polaris ... [Published PE Hub Blog - Jun 24 2014]
First reported Jun 23 2014 - Updated Jun 23 2014 - 1 reports

Flagship VentureLabs: A look inside the place where new biotechs are born

Flagship’s in-house incubator, Flagship VentureLabs, has produced successful biotechs in recent years, including Eleven Biotherapeutics, Moderna Therapeutics and the just-launched Seres Health.I recently spoke with David Berry, a partner at the firm who ... [Published Business First of Buffalo - Jun 23 2014]
First reported Jun 10 2014 - Updated Jun 10 2014 - 1 reports

VC-backed Syros Pharmaceuticals hires new CFO

Syros Pharmaceuticals said Tuesday that it has hired Jorge Conde as chief financial officer and chief product officer. Previously, Conde was the co-founder and CFO of Knome . Based in Watertown, Mass., Syros is focused on treating cancer and other ... [Published PE Hub Blog - Jun 10 2014]
First reported Jun 09 2014 - Updated Jun 09 2014 - 1 reports

Seres Health pulls in $10 mln Series B

Seres Health said Monday that it has received $10 million in Series B funding. The investors included Flagship Ventures, Enso Ventures, Mayo Clinic and Alexandria Venture Investments . Based in Cambridge, Mass., Seres Health is a clinical stage ... [Published PE Hub Blog - Jun 09 2014]

Quotes

...Roger J Pomerantz , President, CEO and Chairman of Seres Health. "The clinical profile of SER-109 demonstrates the power of Seres Microbiome Therapeutics TM discovery platform and gives us high expectations for the advancement of Ecobiotic® candidates in our pipeline for first-line CDI and other serious infections, as well as metabolic disorders and inflammatory conditions."
...Pomerantz.  "I am excited to build on Flagship's reputation as one of the leading innovators in therapeutic discovery and development."
...Roger J Pomerantz , President, CEO and Chairman of Seres Health. "We are driven to obtaining strong patent protection for SER-109, as well as our other clinical candidates, as we continue development with the goal of bringing our first-in-field product to patients."
"It is a huge privilege to be invited to lead Onkaido," said Dr. Kelsey. "Moderna's mRNA platform holds great potential for many therapeutic areas but especially for oncology, a field with many targets still undiscovered. With mRNA Therapeutics, we have the opportunity to rapidly develop new cancer therapies that address unmet medical needs currently untreatable by existing approaches."

More Content

All (45) | News (31) | Reports (0) | Blogs (12) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Atlas biotech gets $29M to create healing bacte... [Published Business First of Buffalo - Jul 22 2014]
How A Little Serendipity Led Acceleron to a Cri... [Published Xconomy - Jul 17 2014]
Seventh Sense Biosystems Receives Notices of Al... [Published Business Wire - Jul 17 2014]
Seres Makes Push for First Drug, and IPO, of Mi... [Published Xconomy - Jul 16 2014]
Seres Health Completes Enrollment in a Clinical... [Published A.M. Best - Jul 16 2014]
Flagship brings aboard ex-Merck & Co exec Pomer... [Published AltAssets.net - Jul 15 2014]
Flagship Ventures Adds Pharma Industry Veteran ... [Published Dow Jones Financial Information Services - Jul 14 2014]
Flagship Ventures expands team with new addition [Published PE Hub Blog - Jul 14 2014]
Flagship Ventures Adds Pharma Industry Veteran ... [Published Good Day Sacramento - Jul 14 2014]
Flagship Ventures Adds Pharma Industry Veteran ... [Published Financial Services - Jul 14 2014]
Movers and Shakers July 2014 [Published PM 360 - Jul 11 2014]
BetaBoston Four Boston biotech firms worth watc... [Published Boston Globe - Jul 07 2014]
Seres Health Announces Allowance for Key Patent... [Published Vision Monday - Jul 07 2014]
Diagnostics developer T2 Biosystems files for a... [Published Nasdaq - Jul 02 2014]
Diagnostics developer T2 Biosystems files for a... [Published Renaissance Capital - Jul 02 2014]
Joule First to Gain US EPA Clearance for Commer... [Published Crawford Financial Planning - Jul 01 2014]
Moderna Appoints Genentech Alum to Lead New Ven... [Published Dow Jones Financial Information Services - Jul 01 2014]
Moderna Appoints Oncology Leader Dr. Stephen Ke... [Published WTOC TV - Jul 01 2014]
Moderna Appoints Oncology Leader Dr. Stephen Ke... [Published TickerTech.com - Jul 01 2014]
Katrine Bosley, Former Avila CEO, Takes Helm at... [Published Xconomy - Jun 24 2014]
VC-backed Editas Medicine hires CEO [Published PE Hub Blog - Jun 24 2014]
Katrine S. Bosley is the new chief executive of... [Published Boston Globe - Jun 24 2014]
Editas Medicine Appoints Katrine S. Bosley to C... [Published BioPortfolio - Jun 24 2014]
Flagship VentureLabs: A look inside the place w... [Published Business First of Buffalo - Jun 23 2014]
Moderna Named to CNBC Disruptor 50 List [Published PR Newswire - Jun 17 2014]
VC-backed Syros Pharmaceuticals hires new CFO [Published PE Hub Blog - Jun 10 2014]
Seres Health pulls in $10 mln Series B [Published PE Hub Blog - Jun 09 2014]
Flagship Ventures Partner David Berry Named a 2... [Published PR Newswire: Financial Services - Mar 11 2014]
Top ten emerging technologies which could shape... [Published Telegraph - Feb 26 2014]
Financings of the Fortnight And the Neverending... [Published The IN VIVO Blog - Feb 21 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Flagship Ventures expands team with new addition [Published PE Hub Blog - Jul 14 2014]
Flagship Ventures said Monday that it has hired Dr. Roger J. Pomerantz as a senior partner. Most recently, Pomerantz served as senior vice president and worldwide head of licensing & acquisitions at Merck & Co . PRESS RELEASE CAMBRIDGE, Mass., July ...
VC-backed Editas Medicine hires CEO [Published PE Hub Blog - Jun 24 2014]
Editas Medicine has hired Katrine S. Bosley as CEO. Previously, Bosley worked at Avila Therapeutics where she served as CEO. Based in Cambridge, Mass., Editas Medicine is a transformative genome editing firm. It is backed by Flagship Ventures, Polaris ...
VC-backed Syros Pharmaceuticals hires new CFO [Published PE Hub Blog - Jun 10 2014]
Syros Pharmaceuticals said Tuesday that it has hired Jorge Conde as chief financial officer and chief product officer. Previously, Conde was the co-founder and CFO of Knome . Based in Watertown, Mass., Syros is focused on treating cancer and other ...
Seres Health pulls in $10 mln Series B [Published PE Hub Blog - Jun 09 2014]
Seres Health said Monday that it has received $10 million in Series B funding. The investors included Flagship Ventures, Enso Ventures, Mayo Clinic and Alexandria Venture Investments . Based in Cambridge, Mass., Seres Health is a clinical stage ...
Flagship Ventures Partner David Berry Named a 2... [Published PR Newswire: Financial Services - Mar 11 2014]
CAMBRIDGE, Mass., March 11, 2014 /PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on healthcare and sustainability, today announced that Dr. David Berry, Partner at Flagship Ventures, has been selected by ...
1 2 3

Press Releases

sort by: Date | Relevance
Flagship Ventures Adds Pharma Industry Veteran ... [Published Financial Services - Jul 14 2014]
Flagship VentureLabs™ Launches Pronutria to Pre... [Published PR Newswire - Oct 22 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.